Your browser doesn't support javascript.
loading
The Score Card Approach: A First Step Toward an Evidence-based Differentiation Assessment for Tablets.
Pekari, Klaus; Fürst, Thomas; Gössl, Rüdiger; Dudhedia, Mayur S; Segretario, James; Sommer, Florian; Watson, Patricia.
Afiliación
  • Pekari K; 1 Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.
  • Fürst T; 1 Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.
  • Gössl R; 2 Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany.
  • Dudhedia MS; 3 Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.
  • Segretario J; 3 Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.
  • Sommer F; 1 Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.
  • Watson P; 3 Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.
Ther Innov Regul Sci ; 50(2): 204-212, 2016 Mar.
Article en En | MEDLINE | ID: mdl-30227008
ABSTRACT

BACKGROUND:

The differentiation of tablets by their physical appearance is a contributing factor to the safe use of medications. In this study, a "score card" was developed to assess how well one tablet is differentiated from another tablet on the basis of the physical attributes of color, size, and shape.

METHODS:

The score card was derived from a "2-out-of-5" difference test, in which participants were presented with groups of 5 tablets with varying color, size, and shape, and were asked to identify the 2 tablets that were different from the other 3 tablets.

RESULTS:

Based on the study results (ie, recognition rate of the differences in the tablets, and confidence in such recognition), simplified metrics were derived to "score" a comparison of 2 tablets differing in color, size, and/or shape. The higher the score, the better the 2 tablets could be visually distinguished from each other. The scores were ranked as representing "strong," "moderate," or "weak" differentiation, with a corresponding stoplight color code, to create the final score card. The score card was internally verified by applying it to the tablets used in the study, then to the multiple strengths of Gilotrif® (afatinib) tablets, a Boehringer Ingelheim approved drug product.

CONCLUSION:

The score card is a first step in the assessment of adequate differentiation of tablets and can be used for the design of tablets that promote safe use of medication.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Ther Innov Regul Sci Año: 2016 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: CH / SUIZA / SUÍÇA / SWITZERLAND

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Ther Innov Regul Sci Año: 2016 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: CH / SUIZA / SUÍÇA / SWITZERLAND